India Glycols: Apportionment of C ost of A cquisition of Equity Shares of India Glycols Limited ("Demerg ed Company"/"the…
India Glycols (INDIAGLYCO) filed a disclosure titled "Apportionment of C ost of A cquisition of Equity Shares of India Glycols Limited ("Demerg ed Company"/"the Company"), Ennature Bio Pharma Limited ("Resulting Company 1") and IGL…". The company is valued…
What happened
India Glycols (INDIAGLYCO) filed a disclosure with the exchanges on 6 October 2026 at 06:02 PM titled "Apportionment of C ost of A cquisition of Equity Shares of India Glycols Limited ("Demerg ed Company"/"the Company"), Ennature Bio Pharma Limited ("Resulting Company 1") and IGL…".
Company snapshot
India Glycols is a small-cap company in the Fast Moving Consumer Goods sector, with a market value of about ₹2,138 crore.
The stock last traded at ₹319, against a 52-week range of ₹164.3–₹1,222 (73.9% below the high).
Before this filing the shares had moved +22.3% over the month and −71.9% over three months. Average daily turnover over the last 20 sessions was about ₹21.26 crore.
Promoters held 59.63% at the end of Q1 FY27. Foreign institutions owned 2.24% and domestic institutions 5.22%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 2,503 | 73.3 | 23.66 |
| Q2 FY26 | 2,412 | 65.1 | 10.51 |
| Q3 FY26 | 2,551 | 67.6 | 10.79 |
| Q4 FY26 | 2,360 | 86.9 | 13.64 |
| Q1 FY27 | 2,988 | 96.8 | 14.45 |
What history shows
BCEIE's records show 12 or more previous m&a filings from the company since May 2026.
After those filings, the stock gained 4.9% on average the next trading day and was down 1.6% on average after five days (11 filings with price data).
Across 63 similar disclosures by other Fast Moving Consumer Goods companies, shares moved −0.3% on average the next day and +0.5% over five days; 37% of them rose the next day.
Market-wide, 1,961 m&a filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 49% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 8 Sept 2026 | 'Material Update in Connection with Ennature Bio Pharma Limited'. | +8.2% | −7.2% |
| 8 Sept 2026 | 'Material Update in Connection with IGL Spirits Limited'. | +8.2% | −7.2% |
| 7 Sept 2026 | M&A | +10.2% | +2.5% |
| 7 Sept 2026 | M&A | +10.2% | +2.5% |
| 21 Aug 2026 | Material Update In Connection With IGL Spirits Limited With… | +2.1% | +0.1% |
What to watch
- Regulatory approvals, completion of the deal and its effect on revenue and margins.
In the news
Recent coverage elsewhere (links open the original publisher):
- Fuelling India's future with clean and sustainable chemistry: Rupark Sarswat, CEO, India Glycols & V.P. Joshi, Head - R&D, India Glycols
- India Glycols Ltd leads gainers in 'A' group
- India Glycols Ltd. Upper Circuit Today: Price, Data and Peers
- India Glycols schedules analyst meetings and roadshow for Oct 7-8
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.